pis...(put something here)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VRCA down 20% after fda approval because of loan annoucement: Term loan facility would provide for up to $125 mln in non-dilutive capital
BCDA down 35% BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected
KOD: Shares of Kodiak Sciences Inc. (KOD) plummeted 56.9% into record-low territory, and to pace all premarket declines, after the California-based biotechnology company said it decided to discontinue development of wet age-related macular degeneration (AMD) treatment tarcocimab.
8k out: Item 4.02 Non-Reliance On Previously Issued Financial Statements Or A Related Audit Report Or Completed Interim Review.
On January 28, 2021, our majority shareholder at the time, Next Meats Co., Ltd., along with our Board of Directors, took action to ratify, affirm, and approve the issuance of 452,352,298 shares of the Company's restricted common stock to Next Meats Co., Ltd. The shares were originally accounted for based on the fair market value closing price per share of common stock based on the open market at the time. However, the Company has now determined that the subject valuation analysis was not credible resulting in the subject value conclusion to not be meaningful given the issuance should have been accounted for as a common control transaction. As such, it is the Company’s belief that the open market value of its common shares did not, at that time, reflect the true value of the shares.
The share valuation has been adjusted and is, in the Company’s belief, now corrected and accounted for as a common control transaction, with our now wholly owned subsidiary, at a valuation of $0. The $452,352 increase in the resulting par value of common shares on the Company's balance sheet has been offset by a corresponding decrease in additional paid in capital in the equity portion of the Company's balance sheet.
Given the above issuance has now been reclassified as a common control transaction, the Company intends to file amendments to the following reports to rectify the historical error regarding the aforementioned valuation of shares: the Form 10-Q for the period ended January 31, 2021, the Form 10-K for the year ended April 30, 2021, the Form 10-Q for the period ended July 31, 2021, the Form 10-Q for the period ended October 31, 2021, the Form 10-Q for the period ended January 31, 2022, the Form 10-K for the year ended April 30, 2022, the Form 10-Q for the period ended July 31, 2022, the Form 10-Q for the period ended October 31, 2022, and the Form 10-Q for the period ended January 31, 2023.
Our forthcoming Form 10-K for the year ended April 30, 2023, will also include the above share issuance adjusted and reclassified as described above.
The above reclassification of the share issuance as a common control transaction has been discussed with BF Borgers CPA PC, our current independent registered public accountant, who has agreed with the reclassification of the share issuance described herein.
Item 9.01 Financial Statements and Exhibits.
None.
https://www.otcmarkets.com/stock/NXMH/disclosure
You're so old! 😉
yes bought boatload on tuesday and sold it all in premarket today
VIR down 45% Vir Biotechnology has seen declining revenue because sales of its one marketed product, Sotrovimab, are declining. A phase 2 trial for an influenza A therapy didn't meet primary or secondary endpoints.
https://news.beeken.io/news-preview?utm_content=newsfeed-Healthcare-VIR&content=U2FsdGVkX1%2Bm6UsQoXfUrmCT45f%2BkGqKuKyHZbYZJzB2lYgxlxv98ZHHDG4U2J%2BOfLDh6hnXcy%2FYi25OyH%2Fb8GGp15zY7P9eB7HDBWx3CKhchFdImu2Eu86ZFiHQmqcYwKXeSfGcJdi1QKlr5dEHOqkYANjL7ZVcT9jIuDIClGmjvXRVRhoNrfjFhkTQcvbwrZathf1sVYsuV1vo4XA2xcBMCj3OdxJlF9A%2FSSsj91cuJ6nLi8vFKiNaBXYadY3JtxNd8XQUWcHFl2M3XOndy6sJpSzq%2Fh7wGGnUHliQVmEYpweuLO0gnRGA7Lbrlor%2Bl0I4wlASlyUx%2FAeQdJhFOP%2BI%2FKTsm2pgmcO2VzusBGcAz57OcavkdCt45Tob1qB1YecCyl77Gs0%2FxSiy3L9YdV4G4IE5xLqvOejNcb9TY8AWRgff7TcX0skMmtcE%2BEUhhnCVtdcAElWZuIfn8BHd6xlzmVpIS0BiYpH%2B24gYrVDf%2FLfipbNS912TQePxJKPmL3%2FKcz2tUs7U%2FxH%2BB8AG7xl5y030Ldpz10yHTnwOYwpaqaCNcyc5u0Mo5bU4QZQ%2Fd3Yapc0phS6qZfemB9aaOPbbCfYU9AWt4VlpIYz21SJYGBwnSNnz47gvrhMR7pLqVx49FJ0MANZ4BLh4zuBDhbH0agAXuBuDMf%2BbzG%2BVAVi64lW86YCttQ6AE4sf7CpCfKKH0Av4u4MPWVYJeEXVd00ERwSAu5n5%2F3veQiCw%2FBHjP084Bl%2B1khgEVTWAdFpU8UHDXfWSwS7xpehd7zhhhV9wAqUWeorv1f7SybuYqW2z42hSgRVcOxYS1PgF7OBTPrB0ecLL2loa6NCnFtLJzZziaTt1b45yt26QED9l1Ev1%2Ft12NoVOrrxmZkBngT0ETIAWdJ7Ezou4%2F0tCgS6cMyLbR3t54b5y6DhlkU0h6IHWCM7OVwuiYklsTnCH%2BqJl%2FB189pOgclbpfhqVc4L7OyFb3haAdofkjdmioJGn4dY%3D&utm_source=dlvr.it&utm_medium=twitter
AMD down 5% - buying back shares I sold yesterday at 121
TOST down 14% after this was announced 'We made the wrong decision,' CEO says as Toast removes 99-cent fee that angered some customers
Good for customers so why the drop? Because they admit they messed up?
Josh Brown just pumped this one on cnbc yesterday. I happen to like him - one of the better ones.
BPTS down12% 1,333,334 units, each consisting of one (1) American Depositary Share ("ADS") or one (1) prefunded warrant giving right to one (1) ADS (the "prefunded warrants")) and one (1) warrant (the "ordinary warrant") to purchase one (1) ADS, at a purchase price of $2.85 per unit comprising an ADS and $2.84 per unit comprising a prefunded warrant
https://healthstockshub.com/news/nasdaq/bpts/biophytis-announces-3-8-million-registered-direct-offering
AQMS down 27% offering at 1.10
maybe a misprint
3.12 price?????
now down 39% - something has to be wrong for it to drop like this
LIXT down 29% offering $6.00 per share - who isn't issuing offering these days?
GRRR down 35% now - looks like I might want some now.
Roller coaster GRRR down 20%
LIXT down 26% offering at a purchase price of $6.00 per common share
BCAN The base offering consists of 1,733,334 common shares at a price to the public of US$1.50 per share.
JZXN down 50% offering priced at 1.65 - Chinese company
BCAN down 48% - offering but no amount or price announced yet
Yes, I hear you and it seems UnAmerican to root for a company to do bad - but it is what it is.
https://www.nasdaq.com/articles/how-short-selling-makes-markets-more-efficient-2020-10-01
I don't short. But I believe it is a necessary function.
No good comes from what they do. That's not true. Shorters actually help keep the market liquid.
CYRX down 25% they issued a revenue warning and all the genius analysts are downgrading it now
PIXY down 35% -company priced its public offering at $1.50 a share.
BDRX another one that was up yesterday and now down 16%
PRFX down 25% pm - was up hugely yesterday.
ALLR down 55% on offering - price of $4.50 per share - Looks like a POS- they did two reverse splits recently:
Jun. 29, 2023 1:40
Mar. 27, 2023 1:35
CRMD down 21% 7,500,000 shares of its common stock at a public offering price of $4.00 per share
BTAI what a nice bounce on that one in premarket - I missed it
ACET another one 56% - says data was positive but questions unanswered
ALVR down 30% offering priced at 3.75
LUCY down another 41% this morning. Offering priced at 1.05. I traded it about five times over the past two days - sold all of it at the close yesterday lucky for me. I don't think I will try it again.
Who are you? lol I guess that's what they do.
LUCY was up big in premarket on news and now it is in the red Innovative Eyewear, which sells so-called smart glasses under various brands, said it has struck a deal with Authentic Brands Group to license the Reebok brand for smart glasses Bought some on the down drop.
DFLI down 43% offering priced at 2
saw that yesterday - too scary - didn't play
PBLA down 52% offering price of $3.75 per share
BBLG Shares of Bone Biologics have lost half their value after the company's underwritten public offering was priced at $1.97 a share.